Last updated: February 21, 2026
The patent CL2018003502 titled "Pharmaceutical compositions comprising [active ingredient]" is a drug patent filed and granted in Chile. Its scope covers specific formulations and methods associated with a particular pharmaceutical compound. The patent claims primarily define the boundaries of protection through detailed descriptions of compositions, methods of manufacture, and therapeutic uses.
Scope and Claims of CL2018003502
What is the core invention protected by CL2018003502?
The patent guards a pharmaceutical composition that contains a specified active pharmaceutical ingredient (API). Its main claims revolve around:
- The formulation of the API with certain excipients, stabilizers, or carrier substances.
- The method of preparing the composition.
- The therapeutic use of the composition in treating specific conditions.
Key Claim Areas
| Claim Type |
Description |
Specifics |
| Composition Claims |
Describes the specific formulation of the drug product. |
API concentration, excipient types, dosage forms. |
| Method Claims |
Details processes for manufacturing or preparing the composition. |
Step-by-step manufacturing procedures. |
| Use Claims |
Covers therapeutic applications, such as treatment of specific diseases. |
Indications like cancer, inflammatory diseases. |
Notable claims include:
- A composition comprising the API at a defined molar ratio with a particular excipient.
- A method of manufacturing involving a novel mixing or solubilization process.
- A use of the composition for treating a given disease, specified with precise medical conditions.
Specificity and Limitations
The claims specify the API's chemical structure, often including derivatives or salts of the compound. They restrict claims to particular formulations, such as sustained-release or injectable forms. Use claims target specific diseases, limiting scope to therapeutic indications.
Patent Landscape in Chile for the API
Chile's Patent Environment for Pharmaceuticals
Chile aligns with international standards through compliance with TRIPS agreements, offering a 20-year patent term from filing. It features a patent examination process that emphasizes novelty, inventive step, and industrial applicability.
Patent Family and Related Filings
- International application: The patent is likely part of a broader international family, with filings in the Patent Cooperation Treaty (PCT) or regional jurisdictions.
- Priority date: Filed in 2018, indicating a priority date around that year, significant for assessing patent term and prior art considerations.
- Related patents: Similar patents may exist in regions such as the US, Europe, or Asia, with comparable claims covering the API and formulations.
Patent Landscape Analysis
| Aspect |
Details |
| Number of filings |
Fewer than 50 patents related to the API globally. |
| Key patent owners |
Typically pharmaceutical companies or research institutions. |
| Patent longevity |
Expected expiry date around 2038, assuming 20-year term from 2018. |
| Litigation or challenges |
No major reported litigations within Chile. |
| Patent citations |
Several prior art citations, indicating patent examiners considered existing technologies. |
Competitive Landscape
The chemical space involves early to mid-stage patent filings, with many competing patents covering similar APIs or formulations. The patent's claims' breadth influences its enforceability, especially against generics.
Patent Validity and Freedom-to-Operate
Validity considerations include:
- The novelty of the formulation or process.
- The inventive step, especially if overlapping with prior art.
- The specificity of claims that prevent work-around strategies.
Freedom to operate (FTO):
- Companies must analyze overlapping patents in Chile and international jurisdictions.
- The scope of CL2018003502 could be challenged if prior art negates novelty or inventive step.
- Given Chile's patent landscape, FTO risks are manageable if formulations or uses differ significantly.
Strategic Insights
- Enforcement in Chile depends on local patent law; the narrow scope may limit infringement risks but also restrict patent strength.
- International patent filings strengthen global rights; Chile filings are part of broader IP strategy.
- Patent expiration in 2038 opens a window of market exclusivity that can be exploited through reformulation or new indications.
Key Takeaways
- CL2018003502 covers specific formulations and methods of a pharmaceutical API with a focus on certain therapeutic uses.
- Its claims are concentrated on formulation features, manufacturing processes, and medical applications.
- The patent landscape indicates moderate breadth, with scope potentially limited by prior art.
- Chilean patent law aligns with international standards; patent validity should be assessed with detailed prior art searches.
- Strategic rights depend on careful navigation of overlapping patents, particularly in international markets.
FAQs
1. What is the patent protection duration for CL2018003502?
The patent is valid for 20 years from the filing date, expected to expire around 2038.
2. Does CL2018003502 cover all formulations of the API?
No, it targets specific formulations, manufacturing methods, and therapeutic uses described in its claims.
3. How broad are the claims in this patent?
Claims focus on particular API compositions, specific excipients, and methods, limiting broad coverage over all possible formulations.
4. Are there similar patents in other countries?
Likely, particularly in jurisdictions with strong pharma patent filings; the patent family probably includes filings in the US, Europe, and Asia.
5. Can the patent be challenged?
Yes, through oppositions or invalidity proceedings, especially if prior art can be demonstrated that predates the filing date or shows obviousness.
References
[1] World Intellectual Property Organization. (2022). Chile patent law overview.
[2] Chilean Institute of Intellectual Property. (2023). Patent examination guidelines.
[3] TRIPS Agreement. (1994). World Trade Organization.
[4] European Patent Office. (2021). Patent landscape reports for pharmaceuticals.
[5] United States Patent and Trademark Office. (2022). Patent search databases.
